Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 783-789

  Lefrère, Jean Jacques ^a   Roudot Thoraval, Françoise ^b   Morand Joubert, Laurence ^b   Petit, Jean Claude ^b   Lerable, Joelle ^b   Thauvin, Micheline ^b   Mariotti, Martine ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION; SUPERINFECTION; SURVIVAL RATE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; CARRIER STATE; CD4 LYMPHOCYTE COUNT; FEMALE; FLAVIVIRIDAE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRUS REPLICATION;

EID: 0032948091     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314671     Document Type: Article

References (30)

1. Simons JN, Pilot-Matias TJ, Leary TP, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 1995;92:3401-5.
2. Linnen J, Wages J, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-9.
3. Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996;334:1536-7.
4. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336:747-54.
5. Masuko K, Mitsui T, Iwano K, et al. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 1996;334:1485-90.
6. Wang JT, Tsai FC, Lee CZ, et al. A prospective study of transfusion-transmitted GB virus C infection: similar frequency but different presentation compared with hepatitis C virus. Blood 1996;88:1881-6.
7. Lefrère JJ, Mariotti M, Lerable J, Thauvin M, Girot R. Long-term persistence of hepatitis G virus in immunocompetent patients. Lancet 1996;348:1174-5.
8. Kudo T, Morishima T, Tsuzuki K, Orito E, Mizokami M. Hepatitis G virus in immunosuppressed paediatric allograft recipients [letter]. Lancet 1996;348:751.
9. Lefrère JJ, Loiseau P, Maury J, et al. Natural history of GBV-C/hepatitis G virus (HGV) infection through the follow-up of GBV-C/HGV infected blood donors and recipients studied by RNA PCR and anti-E2 serology. Blood 1997;90:3776-80.
10. Dille BJ, Surowy TK, Gutierrez RA, et al. An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis 1997;175:458-61.
11. Tacke M. Kiyosawa K, Stark K, et al. Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet 1997;349:318-20.
12. Pilot-Matias TJ, Carrick RJ, Coleman PF, et al. Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology 1996;225:282-92.
13. Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Prevalence of GBV-C/hepatitis G virus (HGV) RNA and of anti-E2 antibody in individuals at high risk of blood-borne or sexually-transmitted viruses: evidence of sexual and parenteral transmission. Transfusion 1999;39:83-94.
14. Heringlake S, Ockenga J, Tillmann HL, et al. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis 1998;177:1723-6.
15. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 1995;346:1131-2.
16. Bogard M, Buffet-Janvresse C, Cantaloube JF, et al. GEMHEP multicenter quality control study of PCR detection of GB virus C/hepatitis G virus RNA in serum. J Clin Microbiol 1997;35:3298-300.
17. TM isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991;35:273-86.
18. van Gemen B, van Beuningen R, Nabbe A, van Strijp D, Jurriaans S, Lens P, Kievits T. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994;49:157-67.
19. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
20. Dixon WJ, Brown MB, Engelman L, Jennrich RI, eds. BMDP statistical software. Berkeley, CA: University of California Press, 1990.
21. Toyoda H, Fukuda Y, Hayakawa T, Takamatsu J, Saito H. Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:209-13.
22. Munoz A, Wang MC, Bass S, et al. Acquired immunodeficiency syndrome (AIDS) free time after human immunodeficiency vims type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am J Epidemiol 1989;130:530-9.
23. Phair J, Jacobson L, Detels R, et al. Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type 1: the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1992;5:490-6.
24. Cao Y, Qin L, Zhang L, Safrit J, Ho DD, Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type I infection. N Engl J Med 1995;332:201-8.
25. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-16.
26. Lefrère JJ, Morand-Joubert L, Mariotti M, et al. Even individuals considered as "long-term nonprogressors" show biological signs of progression after ten years of human immunodeficiency virus (HIV) infection. Blood 1997;90:1133-40.
27. Lefrère JJ, Roudot-Thoraval F, Mariotti M, Thauvin M, Lerable J, Morand-Joubert L. The risk of disease progression is determined since the first year of human immunodeficiency virus infection. J Infect Dis 1998;177:1541-8.
28. Lau JYN, Qian KP, Demer J, et al. Effect of interferon-alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV. J Infect Dis 1997;176:421-6.
29. Pessoa MG, Terrault NA, Ferrell LD, et al. Hepatitis G virus in patients with cryptogenetic liver disease undergoing liver transplantation. Hepatology 1997;25:1266-70.
30. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.